Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
PR Newswire•07/10/2026•07:00 ET
0
Key Highlights
- ➤DAYBREAK met primary endpoints for Zenkuda and tabirafusp-ted in wet AMD
- ➤Zenkuda and tabirafusp-ted delivered non-inferior Year 1 vision gains versus aflibercept
- ➤Kodiak will present Phase 3 GLOW2 diabetic retinopathy data at AAO 2026
- ➤Kodiak will present Phase 1b APEX KSI-101 data in inflammatory macular edema
- ➤DAYBREAK results receive first scientific presentation at AAO 2026 on October 9
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026 PR Newswire
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026.
Get started
Create a free account to read the full story.